Pfizer Inc (NYSE: PFE)’s stock price has plunge by -4.69relation to previous closing price of 26.02. Nevertheless, the company has seen a -7.19% plunge in its stock price over the last five trading sessions. forbes.com reported 2024-11-15 that Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.
Is It Worth Investing in Pfizer Inc (NYSE: PFE) Right Now?
Pfizer Inc (NYSE: PFE) has a higher price-to-earnings ratio of 33.34x compared to its average ratio, The 36-month beta value for PFE is at 0.63. Analysts have varying views on the stock, with 11 analysts rating it as a “buy,” 3 rating it as “overweight,” 14 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PFE is 5.67B, and currently, shorts hold a 1.09% of that float. The average trading volume for PFE on November 18, 2024 was 33.59M shares.
PFE’s Market Performance
The stock of Pfizer Inc (PFE) has seen a -7.19% decrease in the past week, with a -15.27% drop in the past month, and a -13.89% fall in the past quarter. The volatility ratio for the week is 3.22%, and the volatility levels for the past 30 days are at 2.03% for PFE. The simple moving average for the last 20 days is -10.34% for PFE stock, with a simple moving average of -11.91% for the last 200 days.
Analysts’ Opinion of PFE
Many brokerage firms have already submitted their reports for PFE stocks, with Wolfe Research repeating the rating for PFE by listing it as a “Underperform.” The predicted price for PFE in the upcoming period, according to Wolfe Research is $25 based on the research report published on November 15, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see PFE reach a price target of $30. The rating they have provided for PFE stocks is “Neutral” according to the report published on October 25th, 2024.
Bernstein gave a rating of “Mkt Perform” to PFE, setting the target price at $32 in the report published on October 17th of the current year.
PFE Trading at -13.40% from the 50-Day Moving Average
After a stumble in the market that brought PFE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.37% of loss for the given period.
Volatility was left at 2.03%, however, over the last 30 days, the volatility rate increased by 3.22%, as shares sank -15.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.17% lower at present.
During the last 5 trading sessions, PFE fell by -7.19%, which changed the moving average for the period of 200-days by -9.12% in comparison to the 20-day moving average, which settled at $27.66. In addition, Pfizer Inc saw -13.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PFE starting from Gottlieb Scott, who purchase 1,000 shares at the price of $28.24 back on Oct 30 ’24. After this action, Gottlieb Scott now owns 10,000 shares of Pfizer Inc, valued at $28,240 using the latest closing price.
DAMICO JENNIFER B., the SVP & Controller of Pfizer Inc, sale 5,154 shares at $28.66 during a trade that took place back on Aug 13 ’24, which means that DAMICO JENNIFER B. is holding 8,582 shares at $147,714 based on the most recent closing price.
Stock Fundamentals for PFE
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.61 for the gross margin
The net margin for Pfizer Inc stands at 0.07. The total capital return value is set at 0.06. Equity return is now at value 4.52, with 1.97 for asset returns.
Based on Pfizer Inc (PFE), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at 0.73. The interest coverage ratio of the stock is 3.33.
Currently, EBITDA for the company is 9.56 billion with net debt to EBITDA at 4.74. When we switch over and look at the enterprise to sales, we see a ratio of 3.43. The receivables turnover for the company is 4.16for trailing twelve months and the total asset turnover is 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.00.
Conclusion
In conclusion, Pfizer Inc (PFE) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
